ArticleCureus2025
A Randomized Controlled Trial to Compare the Role of Intravenous Iron Sucrose Versus Oral Ferrous Ascorbate for the Prophylaxis of Anemia in Pregnant Women.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Anemia in pregnancy is a significant health concern, particularly in low- and middle-income countries such as India. Iron deficiency anemia (IDA) is its most common cause, leading to adverse maternal and fetal outcomes. While oral iron (OI) therapy is the standard prophylaxis, poor compliance due to gastrointestinal side effects limits its effectiveness. Intravenous iron sucrose (IVIS) may provide an alternative with better tolerability. This study aimed to compare the efficacy, safety, and compliance of IVIS versus OI for anemia prophylaxis in pregnant women. Materials and methods A randomized controlled trial was conducted at Shri BM. Patil Medical College, Hospital and Research Centre, Vijayapura, Karnataka, over 12 months. A total of 100 antenatal women with hemoglobin (Hb) ≥11 g/dL were randomized into two groups: Group A received IVIS 200 mg in 100 mL normal saline at 20-24, 24-28, and 28-32 weeks, and Group B received OI 100 mg daily till 32 weeks. Hematological parameters and serum ferritin were measured at baseline, four weeks, and 12 weeks of treatment. Side effects, compliance, and cost of the treatment were assessed. Results Group A showed a significantly greater increase in Hb (12.19 ± 0.68 g/dL) compared to Group B (11.63 ± 0.74 g/dL) at 12 weeks (p<0.0001). Serum ferritin levels were significantly higher in Group A (163.26 ± 76.28 ng/mL) versus Group B (81.28 ± 65.98 ng/mL) (p<0.0001). Gastrointestinal side effects were more common in the oral group. Notably, the cost of treatment for Group A was also lower Conclusions Based on our findings, IVIS is more effective, better tolerated, and improves iron stores significantly compared to OI for the prophylaxis of anemia in pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.